The paperwork alone can crush you. A single 510(k) filing—the relatively straightforward pathway for most medical devices—runs to thousands of pages: clinical trial results, risk assessments, comparisons to existing products on the market, all meticulously cross-referenced against a labyrinth of FDA guidance documents that even career regulators admit can be maddeningly inconsistent. Most young biotech companies and device makers spend months on this, hemorrhaging cash to consultants who bill by the hour and whose timelines have a way of stretching longer than anyone planned.
Panacea, a San Francisco startup from Y Combinator's Spring 2026 batch, is betting there's a faster, cheaper way through the maze.
The Pitch: AI Does the Grunt Work, Humans Make the Calls
Launching in May 2026, Panacea has styled itself as an "AI-Native FDA Regulatory Team"—a hybrid service that pairs former FDA consultants with a proprietary AI platform designed specifically for regulatory filings. The company covers the full range of FDA pathways: 510(k), De Novo, and PMA submissions for medical devices; IND, NDA, and BLA applications for drugs; plus specialized routes like orphan drug designations and breakthrough device pathways.
The economics are the real hook here. Panacea offers fixed-price contracts tied to milestones—clients pay only when agreed deliverables are finished. No hourly billing, no scope creep, no surprise invoices when a consultant decides the project needs another round of revisions. According to the company, its AI handles roughly 90 percent of what it calls the "manual grunt work": mining legacy FDA databases, parsing decades of guidance documents, drafting the initial skeleton of submissions. The human experts—the ex-regulators and consultants—step in for strategy, nuanced interpretation, and the final review before a submission goes out the door.
One consultant featured on Panacea's website claims delivery times are "12x faster" using the platform. But that's a vendor-supplied testimonial, and there's no independent verification to back up the number.
The Founders: Healthtech Veterans With AI Chops
Behind Panacea are Haris Javed-Akhtar and Yaman Ziadeh, both alumni of Anterior, a well-funded healthtech company backed by Sequoia and NEA. Javed-Akhtar, who earned his MD from Imperial College, previously ran go-to-market partnerships at Anterior. Ziadeh, the technical co-founder, worked as an AI platform engineer there—and before that, at Bloomberg. He also co-founded Baqi, a venture he scaled to more than $3 million in transactions and over 20 enterprise partnerships before moving on.
The team size is listed as two on Y Combinator's directory as of May 2026, though that figure may not reflect recent hires. A LinkedIn post from a third party claims Panacea went from "0 → mid 6-figures of contracted revenue during YC," but the company hasn't confirmed the amount publicly.
Riding a Wave—or Creating One?
The timing is interesting, if nothing else. Panacea is entering a regulatory landscape that's both more Byzantine than ever and, oddly, more open to AI. On May 6, 2026, the FDA announced expanded AI capabilities and the completion of a data platform consolidation—building on the Elsa 1.0 system it launched back in June 2025. The agency itself is now using AI to comb through the more than 40 application data sources it manages internally. In other words, the regulators are drinking their own Kool-Aid.
Meanwhile, the number of AI-enabled medical devices hitting the market keeps climbing. April 2026 alone saw 27 AI and machine learning devices authorized, part of a multi-year surge. By the end of 2025, more than 1,200 AI-enabled medical devices had received U.S. marketing authorization.
And Panacea isn't the only one circling this opportunity. Complizen offers an "FDA Co-Pilot" that promises to build 510(k) submissions in 8 to 12 weeks. Rhizome AI, another Y Combinator alum, sells regulatory intelligence tools. In February, Ketryx unveiled what it calls "validated AI agents" for regulated industries. Even the incumbents are moving—Parexel, one of the industry's biggest contract research organizations, partnered with Weave Bio to co-develop regulatory workflows, and Weave launched NDA workflow capabilities in late April.
Panacea's play is to own the whole stack—to sell outcomes, not just software. In a market where sponsors are exhausted by tools that still require armies of consultants to operate, that might be a meaningful distinction. Or it might not.
What We Don't Know
Here's what Panacea hasn't disclosed: customer names, average timelines from start to submission, technical specifics about its AI models or data sources. Pricing details beyond the milestone structure remain under wraps. And aside from Y Combinator's standard participation, there's no public record of seed funding, valuation, or additional investors stepping in.
For biotech and medtech founders facing their first FDA filing—or their tenth—Panacea amounts to a wager that AI can compress both the timeline and the cost of a process that hasn't fundamentally changed in decades. Whether the platform actually delivers on that promise at any real scale is still an open question.
What's undeniable is that the regulatory services market, long ruled by hourly consultants and sprawling contract research organizations, now faces a new breed of competitor—one willing to bet its entire pricing model on the strength of its algorithms. That alone is worth watching.
